<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9954">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01949805</url>
  </required_header>
  <id_info>
    <org_study_id>PROUD-PV</org_study_id>
    <secondary_id>2012-005259-18</secondary_id>
    <nct_id>NCT01949805</nct_id>
  </id_info>
  <brief_title>Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera</brief_title>
  <acronym>PROUD-PV</acronym>
  <official_title>A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AOP Orphan Pharmaceuticals AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AOP Orphan Pharmaceuticals AG</source>
  <oversight_info>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <authority>Bulgaria: Ministry of Health</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hungary: Ministry of Health, Social and Family Affairs</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Poland: Ministry of Health</authority>
    <authority>Romania: National Agency for Medicines and Medical Devices</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>Spain: Ministry of Health</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III study to compare the efficacy and safety of the novel monopegylated interferon
      alpha 2b AOP2014 versus Hydroxyurea (the current licensed therapy for this disease). One
      year treatment of patients with polycythemia vera. The hypothesis is that AOP2014 is
      superior to HU to achieve response rates measured after one year. Response is measured as
      normalisation of key lab parameters as well as normalized spleen size.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Disease response rate</measure>
    <time_frame>Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disease response rate is defined as hematocrit &lt;45% without phlebotomy (at least 3 months since last phlebotomy), platelets &lt;400 G/L, leukocytes &lt;10 G/L , and normal spleen size</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disaese response</measure>
    <time_frame>at month 3, 6 and 9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>JAK2 allelic burden changes</measure>
    <time_frame>at month 6 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to response</measure>
    <time_frame>from inclusion until first response confirmation</time_frame>
    <safety_issue>No</safety_issue>
    <description>will be measured during the study period of 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>during the 12 months of study duration</time_frame>
    <safety_issue>No</safety_issue>
    <description>from the first documented response on study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of phlebotomies</measure>
    <time_frame>from inclusion until month 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood parameters</measure>
    <time_frame>from inclusion until month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>biweekly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>spleen size</measure>
    <time_frame>at month 3, 6, 9 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>both centrally (blinded assessment) and locally</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease related symptoms</measure>
    <time_frame>from inclusion until month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>biweekly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>from inclusion until month 12</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>biweekly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>protocol-specific adverse events of special interest</measure>
    <time_frame>from inclusion until month 12</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>biweekly</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Polycythemia Vera</condition>
  <arm_group>
    <arm_group_label>Hydroxyurea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxyurea capsules (500 mg each). Daily intake of doses from 500 mg Q2D to 3000 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peg-P-IFN-alpha-2b (AOP2014)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peg-P-IFN-alpha-2b at 50mcg to max 500 mcg, given every other week as one subcutanous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-P-IFN-alpha-2b (AOP2014)</intervention_name>
    <arm_group_label>Peg-P-IFN-alpha-2b (AOP2014)</arm_group_label>
    <other_name>AOP2104</other_name>
    <other_name>formerly P1101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
    <arm_group_label>Hydroxyurea</arm_group_label>
    <other_name>HU</other_name>
    <other_name>Hydroxycarbamide</other_name>
    <other_name>brand name Litalir (or other)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years or older

          2. Diagnosis of Polycythemia Vera according to the WHO 2008 criteria (Barbui et al,
             2011) with the mandatory presence of JAK2V617F mutation as the major disease
             criterion.

          3. For previously cytoreduction untreated patients - documented need of cytoreductive
             treatment

             - leukocytosis (WBC&gt;10G/L for two measurements within one week)

          4. For patients currently treated or pre-treated with HU,  all of the following
             criteria:

               -  being non responders (as defined by the response criteria for primary endpoint)

               -  total HU treatment duration shorter than three years

               -  no documented resistance or intolerance as defined by modified Barosi et al,
                  2009 criteria

          5. Hospital Anxiety and Depression Scale (HADS) score 0-7 on both subscales

          6. Patients with HADS score of 8-10 inclusive on either or both of the subscales may be
             eligible following psychiatric assessment that excludes clinical significance of the
             observed symptoms in the context of potential treatment with an interferon alpha

          7. Signed written informed consent

        Exclusion Criteria:

          1. Any systematic cytoreduction for PV prior study entry with exception of HU for
             shorter than 3 years (see respective inclusion criterion)

          2. Any contraindication to any of the IMPs (pegylated interferon or hydroxyurea) or
             their excipients

          3. Any systemic exposure to a non-pegylated or pegylated interferon alpha

          4. Documented autoimmune disease at screening or in the medical history

          5. Clinically relevant pulmonary infiltrates, pneumonia, and pneumonitis at screening

          6. Systemic infections, e.g. hepatitis B, hepatitis C, or HIV at screening

          7. Known PV-related thromboembolic complications in the abdominal area (e.g. portal vein
             thrombosis, Budd-chiari syndrome) and/or splenectomy in the medical history

          8. Any investigational drug less than 6 weeks prior to the first dose of study drug or
             not recovered from effects of prior administration of any investigational agent

          9. History or presence of depression requiring treatment with antidepressant

         10. HADS score equal to or above 11 on either or both of the subscales

         11. Any risk of suicide at screening or previous suicide attempts

         12. Any significant morbidity or abnormality which may interfere with the study
             participation

         13. Pregnancy and breast-feeding females of reproductive potential and males not using
             effective means of contraception

         14. History of active substance or alcohol abuse within the last year

         15. Evidence of severe retinopathy (e.g. cytomegalovirus  retinitis, macular
             degeneration) or clinically relevant ophthalmological disorder (due to diabetes
             mellitus or hypertension)

         16. Thyroid dysfunction not adequately controlled

         17. Patients tested positively with TgAb and / or TPOAb at screening

         18. History of major organ transplantation

         19. History of uncontrolled severe seizure disorder

         20. Leukocytopenia at the time of screening

         21. Thrombocytopenia at the time of screening

         22. History of malignant disease, including solid tumours and hematological malignancies
             (except basal cell and squamous cell carcinomas of the skin and carcinoma in situ of
             the cervix that have been completely excised and are considered cured) within the
             last 3 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinz Gisslinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oleh Zahriychuk, MD</last_name>
    <phone>+43-1-5037244</phone>
    <phone_ext>76</phone_ext>
    <email>oleh.zahriychuk@aoporphan.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Zoerer, PhD</last_name>
    <phone>+43-1-5037244</phone>
    <phone_ext>46</phone_ext>
    <email>michael.zoerer@aoporphan.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LKH Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elisabethinen Hospital Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Salzburg Regional Hospital</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hanusch Hospital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Wels-Grieskirchen</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Sveti Georgi&quot;</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Hematological Diseases</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment &quot;Sveta Marina&quot;</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Blood Transfusion</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Kralovske Vinohrady</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute Paoli-Calmettes</name>
      <address>
        <city>Marseilles</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center CIC</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aachen University Hospital, Medical Clinic IV</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn, Center for Internal Medicine, Medical Clinic and Outpatient Clinic III</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Istvan and St Laszlo Hospital of Budapest</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaposi Mor County Teaching Hospital</name>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Careggi University Hospital</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Foundation IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Andrzej Mielecki Independent Public Clinical Hospital of Medical University of Silesia in Katowice</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital in Cracow</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Independent Public Teaching Hospital No.1 in Lublin</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fryderyk Chopin Provincial Specialized Hospital</name>
      <address>
        <city>Rzeszow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nicolaus Copernicus Municipal Specialist Hospital</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Transfusion Medicine</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emergency Clinical County Hospital Brasov</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bucharest University Emergency Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coltea Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>&quot;Prof. Dr. Ion Chiricuta&quot; Institute of Oncology</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baranov Republican Hospital</name>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samara Kalinin Regional Clinical Hospital</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Hospital #15</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Komi Republican Oncology Center</name>
      <address>
        <city>Syktyvkar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tula Regional Clinical Hospital</name>
      <address>
        <city>Tula</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional Clinical Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital with Outpatient Clinic F.D. Roosevelt</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Cyril and Metod University Hospital Bratislava</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cherkasy Regional Oncology Center, Regional Treatment and Diagnostics Hematology Center</name>
      <address>
        <city>Cherkasy</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk City Multispecialty Clinical Hospital #4</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>V.K. Husak Institute of Urgent and Reconstructive Surgery</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Research Center for Radiation Medicine, Institute of Clinical Radiology</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Blood Pathology and Transfusion Medicine</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>O.F. Herbachevskyi Regional Clinical Hospital</name>
      <address>
        <city>Zhytomyr</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 5, 2013</lastchanged_date>
  <firstreceived_date>September 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon Alfa-2a</mesh_term>
    <mesh_term>Interferon Alfa-2b</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Reaferon</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
